<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BJPsych Open</journal-id><journal-id journal-id-type="iso-abbrev">BJPsych Open</journal-id><journal-id journal-id-type="pmc-domain-id">2999</journal-id><journal-id journal-id-type="pmc-domain">bjpsychopen</journal-id><journal-id journal-id-type="publisher-id">BJO</journal-id><journal-title-group><journal-title>BJPsych Open</journal-title></journal-title-group><issn pub-type="epub">2056-4724</issn><publisher><publisher-name>Royal College of Psychiatrists</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11457226</article-id><article-id pub-id-type="pmcid-ver">PMC11457226.1</article-id><article-id pub-id-type="pmcaid">11457226</article-id><article-id pub-id-type="pmcaiid">11457226</article-id><article-id pub-id-type="pmid">39308301</article-id><article-id pub-id-type="doi">10.1192/bjo.2024.780</article-id><article-id pub-id-type="pii">S2056472424007804</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Paper</subject></subj-group></article-categories><title-group><article-title>Characteristics of high-dose benzodiazepine use: nationwide cohort study on new benzodiazepine users with 5-year follow-up</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5819-0586</contrib-id><name name-style="western"><surname>S&#228;rkil&#228;</surname><given-names initials="H">Hanna</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="aff2" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3281-934X</contrib-id><name name-style="western"><surname>Taipale</surname><given-names initials="H">Heidi</given-names></name><xref rid="aff3" ref-type="aff"/><xref rid="aff4" ref-type="aff"/><xref rid="aff5" ref-type="aff"/><xref rid="aff6" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tanskanen</surname><given-names initials="A">Antti</given-names></name><xref rid="aff3" ref-type="aff"/><xref rid="aff4" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kurko</surname><given-names initials="T">Terhi</given-names></name><xref rid="aff5" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Taiminen</surname><given-names initials="T">Tero</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tiihonen</surname><given-names initials="J">Jari</given-names></name><xref rid="aff3" ref-type="aff"/><xref rid="aff4" ref-type="aff"/><xref rid="aff6" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sund</surname><given-names initials="R">Reijo</given-names></name><xref rid="aff7" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saastamoinen</surname><given-names initials="L">Leena</given-names></name><xref rid="aff8" ref-type="aff"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3179-6780</contrib-id><name name-style="western"><surname>Hietala</surname><given-names initials="J">Jarmo</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="aff2" ref-type="aff"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1130-9161</contrib-id><name name-style="western"><surname>Niemel&#228;</surname><given-names initials="S">Solja</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="aff2" ref-type="aff"/></contrib></contrib-group><aff id="aff1">Department of Psychiatry, Clinical Institute, <institution>University of Turku</institution>, <city>Turku</city>, <country>Finland</country></aff><aff id="aff2">Department of Psychiatry, <institution>Turku University Hospital,</institution>&#160;<city>Turku</city>, <country>Finland</country></aff><aff id="aff3">Department of Forensic Psychiatry, <institution>University of Eastern Finland, Niuvanniemi Hospital</institution>, <city>Kuopio</city>, <country>Finland</country></aff><aff id="aff4">Department of Clinical Neuroscience, <institution>Karolinska Institutet</institution>, <city>Stockholm</city>, <country>Sweden</country></aff><aff id="aff5">Research Unit, <institution>The Social Insurance Institution</institution>, <city>Helsinki</city>, <country>Finland</country></aff><aff id="aff6">Center for Psychiatry Research, <institution>Stockholm City Council</institution>, <city>Stockholm</city>, <country>Sweden</country></aff><aff id="aff7">School of Pharmacy, <institution>University of Eastern Finland</institution>, <city>Kuopio</city>, <country>Finland</country></aff><aff id="aff8">Information and Development Services, <institution>Finnish Medicines Agency</institution>, <city>Helsinki</city>, <country>Finland</country></aff><author-notes><corresp id="cor1"><bold>Correspondence:</bold> Hanna S&#228;rkil&#228;. Email: <email>hanna.sarkila@varha.fi</email></corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-09"><month>9</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>23</day><month>9</month><year>2024</year></pub-date><volume>10</volume><issue seq="158">5</issue><issue-id pub-id-type="pmc-issue-id">472293</issue-id><elocation-id>e158</elocation-id><history><date date-type="received"><day>11</day><month>11</month><year>2023</year></date><date date-type="rev-recd"><day>24</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>8</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>09</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-08 10:25:15.110"><day>08</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="S2056472424007804a.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="S2056472424007804a.pdf"/><abstract><sec id="sec_a1"><title>Background</title><p>A nationwide register-based cohort study from Finland including 48 124 incident benzodiazepines and related drug (BZDR) users aged 18&#8211;65 years who initiated use in 2006 and were not dispensed BZDRs during 2004&#8211;2005. The follow-up was 5 years or until death, whichever occurred first.</p></sec><sec id="sec_a2"><title>Aims</title><p>To investigate sociodemographic and clinical factors associated with high-dose use of BZDRs (i.e. Z-drugs) among new BZDR users.</p></sec><sec id="sec_a3"><title>Method</title><p>The temporal BZDR dose was calculated as a point estimate every 6 months after initiation as defined daily doses (DDDs) per day, based on the PRE2DUP method (an approach based on mathematical modelling of personal drug purchasing behaviours). Sociodemographic and clinical factors associated with dose categories were studied using multinomial logistic regression.</p></sec><sec id="sec_a4"><title>Results</title><p>During the 5-year follow-up, very high-dose BZDR use was observed in 7.4% (<italic toggle="yes">n</italic> = 3557) and medium high-dose use in 25.5% (<italic toggle="yes">n</italic> = 12 266) of the users (corresponding to &#8805;30 mg and 10&#8211;29 mg in diazepam equivalents, respectively). Very high-dose use was more common among men compared with women (10.9% versus 4.6%). Very high-dose use patterns were especially observed in younger age groups (18- to 25-year-olds). Compared with oxazepam, initiating BZDR use with clonazepam (adjusted odds ratio 3.86, 95% CI 3.24&#8211;4.60), diazepam (2.05, 1.78&#8211;2.36) or alprazolam (1.76, 1.52&#8211;2.03) was associated with increased odds for very high-dose use. Both medium high-dose and very high-dose BZDR use were associated with a lower level of education. In all, 58% of very high-dose use occurred in BZDR users who received their first prescription from general practitioners.</p></sec><sec id="sec_a5"><title>Conclusions</title><p>Clinicians should be aware of the dose escalation risk especially when prescribing diazepam, alprazolam or clonazepam for psychiatric indications. If BZDRs are needed, our findings suggest favouring oxazepam.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Benzodiazepines</kwd><kwd>Z-drugs</kwd><kwd>sociodemographic factors</kwd><kwd>comorbidity</kwd><kwd>high-dose use</kwd></kwd-group><funding-group><award-group id="aw1"><funding-source><institution>Turku Psychiatric services</institution></funding-source><award-id>Grant 603459</award-id></award-group><award-group id="aw2"><funding-source><institution-wrap><institution>Alkoholitutkimuss&#228;&#228;ti&#246;</institution><institution-id institution-id-type="doi">http://dx.doi.org/10.13039/100016238</institution-id></institution-wrap></funding-source></award-group><award-group id="aw3"><funding-source><institution-wrap><institution>Turun Yliopistollisen Keskussairaalan Koulutus- ja Tutkimuss&#228;&#228;ti&#246;</institution><institution-id institution-id-type="doi">http://dx.doi.org/10.13039/501100009094</institution-id></institution-wrap></funding-source><award-id>Grant P3704</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="4"/><ref-count count="40"/><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Benzodiazepines and related drugs (BZDRs) have been used since the 1960s,<sup><xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref2" ref-type="bibr">2</xref></sup> and their use is common in many countries.<sup><xref rid="ref3" ref-type="bibr">3</xref>,<xref rid="ref4" ref-type="bibr">4</xref></sup> BZDRs enhance inhibitory gamma-aminobutyric acids (GABA) actions in the brain by allosteric modulation of the GABA-A receptor, and induce anxiolytic, sedating and muscle-relaxing effects as well as anticonvulsive effects. When introduced, BZDRs appeared to be less likely to cause adverse effects, but continuous use of BZDRs may lead into unwanted consequences, such as tolerance, dose escalation, use disorder, respiratory failure and problems in everyday functioning.<sup><xref rid="ref5" ref-type="bibr">5</xref>&#8211;<xref rid="ref7" ref-type="bibr">7</xref></sup> Even though previous studies on the potential benefits and harms of BZDR use are partly controversial,<sup><xref rid="ref8" ref-type="bibr">8</xref></sup> many recommendations on the subject have been published over the years.<sup><xref rid="ref9" ref-type="bibr">9</xref>,<xref rid="ref10" ref-type="bibr">10</xref></sup> A majority of them emphasise that the dose and duration of BZDR use should be kept as low and short as possible.<sup><xref rid="ref11" ref-type="bibr">11</xref></sup></p><p>Despite the common use of BZDRs, we have very little high-quality knowledge of risk factors for BZDR dose escalation because the definitions of high-dose use differ and real-world data are not easily available in many countries.<sup><xref rid="ref12" ref-type="bibr">12</xref></sup> Many factors, such as young age, male gender, lower educational level, smoking and alcohol and other substance misuse have been associated with unrecommended high-dose BZDR use.<sup><xref rid="ref4" ref-type="bibr">4</xref>,<xref rid="ref13" ref-type="bibr">13</xref>,<xref rid="ref14" ref-type="bibr">14</xref></sup> However, less is known about factors associated with BZDR dose escalation.<sup><xref rid="ref15" ref-type="bibr">15</xref></sup></p><p>As BZDRs have many known neurobiological and pharmacologic properties that may potentially lead to misuse and physical dependence especially in high doses, the need for further studies is obvious to prevent BZDR-related adverse effects such as cognitive impairment and elevated risks for accidents (vehicle accidents, falls and other traumas). In high doses, BZDRs also pose a risk for toxicity, i.e. impaired coordination, anterograde amnesia, disinhibition, ataxia, vertigo, delirium and inattentiveness, and may lead to fatal overdoses especially when combined with other substances/medications.<sup><xref rid="ref2" ref-type="bibr">2</xref></sup> With this nationwide register-based follow-up study, our aim was thus to investigate the incidence of high-dose BZDR use as well as the sociodemographic and clinical characteristics associated with subsequent development of high-dose BZDR use, and in particular among new BZDR users. BZDRs are still widely used, and the starting point of the large observational study was to produce further information for clinicians for rational BZDR prescribing.</p><sec sec-type="methods" id="sec1"><title>Method</title><p>The study population was collected from the Dispensations reimbursable under the National Health Insurance Scheme register, which is maintained by the Social Insurance Institution of Finland, and contains information on all reimbursed prescription drug purchases. The inclusion criteria for the present study were: (a) initiation of BZDRs during the year 2006, (b) no previous BZDR use from January 2004 until December 2005, and (c) age between 18 to 65 years at initiation. Those who initiated the use with clonazepam or clobazam for epilepsy indication were not included in this study. Those who did not continue BZDR use after the first purchase were excluded, as the dose could not be calculated for these persons. Thus, the final study sample included 48&#160;124 individuals. The follow-up period of this sample was 5 years from the first BZDR purchase. Extremely high BZDR use was also examined in more detail in the &gt;3&#8211;&#8805;10&#160;defined daily doses (DDDs)/day groups, as seen in <xref rid="fig01" ref-type="fig">Fig. 1</xref>.
<fig position="float" id="fig01" fig-type="fig" orientation="portrait"><label>Fig. 1</label><caption><p>The highest measured dose in defined daily doses per day at any point during the 5-year follow-up period among those defined as high-dose users: (a) distribution by gender and (b) distribution of specific drugs used when the highest dose was observed by very high-dose categories. BZD, benzodiazepine; BZDR, benzodiazepines and related drug.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S2056472424007804_fig1.jpg"/></fig></p><p>This study was based solely on register data and, according to Finnish legislation, no ethics approval or patient consent were needed. The register maintainers pseudonymised the register data before granting access to the researchers, and the study subjects were not contacted. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines were followed.</p><sec sec-type="other" id="sec1-1"><title>Outcome</title><p>For defining BZDR use from the Dispensations reimbursable under the National Health Insurance Scheme register, we used the Anatomical Therapeutic Chemical (ATC) classification system, in which the active substances are classified in a hierarchy with five different levels, and further divided into smaller groups based on their qualities and features.<sup><xref rid="ref16" ref-type="bibr">16</xref></sup></p><p>In this study, ATC levels and subgroups used were N03AE01, N05BA (excluding clobazam), N05CD, N05CF and N06CA01 (amitriptyline combined with chlordiazepoxide). Only orally administered dosage forms were included, except for oral suspensions (mainly used for epilepsy indication). BZDRs used in this study were diazepam, oxazepam, alprazolam, zopiclone, zolpidem, temazepam, clonazepam and polypharmacy (two or more drugs concomitantly). Because of the low number of users, the rest of the BZDRs were grouped as &#8216;all others&#8217;, including chlordiazepoxide, lorazepam, clobazam, nitrazepam and amitriptyline combined with chlordiazepoxide.</p><p>We used the PRE2DUP method (an approach based on mathematical modelling of personal drug purchasing behaviours)<sup><xref rid="ref17" ref-type="bibr">17</xref></sup> to calculate the duration of BZDR use, i.e. when the use started and ended. For continuous BZDR use periods, we further calculated a temporal point estimate of dose every 6 months after initiation of use, in defined daily doses (DDDs, i.e. the assumed average maintenance dose per day for a drug used for its main indication in adults), summed from all concomitant specific BZDRs.<sup><xref rid="ref18" ref-type="bibr">18</xref></sup> This method also ensured that the frequency of purchases or survival bias (e.g. being alive for less than 1 year would skew the results when annually defined cumulative amounts are used) did not affect the result. The DDD reference value for clonazepam is for epilepsy indication (8 mg) and, thus, it was changed to 1 mg and was included only when purchased without special reimbursement for epilepsy (used for other than epileptic indications).</p><p>Here, because of the lack of the exact definition for high-dose BZDR use,<sup><xref rid="ref3" ref-type="bibr">3</xref>,<xref rid="ref12" ref-type="bibr">12</xref>,<xref rid="ref19" ref-type="bibr">19</xref></sup> we used a three-class variable with (a) low dose (&lt;1.0&#160;DDDs/day), (b) medium high dose (1.0&#8211;&lt;3.0&#160;DDDs/day) and (c) very high dose (&#8805;3.0&#160;DDDs/day). Thus, the utilised measure for high dose, i.e. 1000&#160;DDDs dispensed during 365 days, was reversed to &#8805;3&#160;DDDs/day (approximating the same amount in daily dose, as 1000&#160;DDDs/365 days&#160;=&#160;2.7&#160;DDDs per day, which was rounded up to the nearest whole number). In diazepam equivalent doses, 10&#160;mg of diazepam converts to 1&#160;DDD. The approximate equivalent doses to 10&#160;mg diazepam are given in Supplementary Table 1 available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1192/bjo.2024.780">https://doi.org/10.1192/bjo.2024.780</uri>, and are based on the research of Professor Ashton.<sup><xref rid="ref20" ref-type="bibr">20</xref></sup></p><p>The dose category defined for each person was the highest dose that person used in any of the ten time points, measured at 6-month intervals during the 5-year follow-up. For the extremely high BZDR doses, we used categories &gt;3&#8211;&#8805;10&#160;DDDs/day.</p></sec><sec sec-type="other" id="sec1-2"><title>Sociodemographic variables</title><p>For sociodemographic information, register data from the Finnish Centre for Pensions, Social Insurance Institution of Finland and Statistics Finland were used. The study included users aged 18&#8211;65 years, with age categories 18&#8211;25, 26&#8211;35, 36&#8211;45, 46&#8211;55 and 56&#8211;65 years.</p><p>Information on social benefits was used to indicate varying life circumstances at the baseline. The Finnish social security system includes various forms of financial support and benefits, which are meant to ensure that everyone has equal opportunities in working life and society. These data were based on registers maintained by the Social Insurance Institution of Finland and defined as receiving social assistance, labour market subsidy, basic unemployment allowance, national pension, study grants, maternity allowance, paternity allowance, parental allowance and child home care allowance during the year 2005. The Finnish Centre for Pensions provided information on disability pensions, which was measured at the time of BZDR initiation. Information on social benefits was pooled and used as a two-class variable (no/yes) in the multivariate analyses.</p><p>Educational level was defined as the highest level the person had completed by the year 2005 and was categorised into three groups: primary and lower secondary education (primary school or less), general upper secondary education/vocational education and training (high school or technical school) and higher education (university). Categories for occupations were defined by utilising the Classification of Occupations from Statistics Finland,<sup><xref rid="ref21" ref-type="bibr">21</xref></sup> where occupational social class is used as a proxy for socioeconomic position. Data were divided to six bigger categories: &#8216;managerial/professional&#8217; as groups 1&#8211;3 (managers, professionals, technicians and associate professionals), &#8216;office worker&#8217; as group 4 (clerical support workers), &#8216;farming/forestry&#8217; as group 6 (skilled agricultural, forestry and fishery workers), &#8216;sales/industry/cleaning&#8217; as groups 5, 7, 8, 9 (service and sales workers, craft and related trades workers, plant and machine operators and assemblers, and elementary occupations) and &#8216;unknown&#8217; as group X (unknown).</p></sec><sec sec-type="other" id="sec1-3"><title>Psychiatric disorders</title><p>The cohort's potential psychiatric disorders including substance use disorder (SUD) were collected from the Care Register for the Health Care maintained by the Finnish Institution for Health and Welfare, diagnosis recorded in the Disability Pension register, and the Special Reimbursement register maintained by the Social Insurance Institution of Finland. The Special Reimbursement register offered information on people who were granted a special refund for drugs due to certain diagnosed chronic diseases. The information on the special refunds was used as a proxy for the condition. The data were then gathered, utilising the International Classification of Diseases (ICD-10) diagnoses, the Anatomical Therapeutic Chemical (ATC)-codes and special reimbursement codes.</p></sec><sec sec-type="other" id="sec1-4"><title>Statistical methods</title><p>The data were analysed using the IBM SPSS software version 27. Dose groups were compared using the <italic toggle="yes">&#967;</italic><sup>2</sup> test for categorical variables and <italic toggle="yes">t</italic>-tests for continuous variables. Multinomial logistic regression was used to estimate odds ratios for medium high-dose and very high-dose users compared with low-dose users. The results are reported as unadjusted and adjusted odds ratios with 95% CI. Data management was conducted with statistical analysis software (SAS) 9.4. Gender, age, level of education, psychiatric disorders including SUD, and social benefits and disability pension status were used as covariates.</p></sec></sec><sec sec-type="results" id="sec2"><title>Results</title><sec sec-type="other" id="sec2-1"><title>Sociodemographic characteristics</title><p>The study cohort included 48&#160;124 individuals (44.4% male, mean age 45.8, s.d. 12.2). The formation of the study sample is presented in more detail in the flowchart in <xref rid="fig02" ref-type="fig">Fig. 2</xref>. During the 5-year follow-up, 25.5% (<italic toggle="yes">n</italic>&#160;=&#160;12&#160;266) of the study population were defined as medium high-dose users, i.e. their highest measured dose at any time point during the follow-up was 1.0&#8211;&lt;3.0&#160;DDDs/day. Very high-dose BZDR use (&#8805;3&#160;DDDs/day) occurred in 7.4% (<italic toggle="yes">n</italic>&#160;=&#160;3557) of the study population. During the 5-year follow-up, 12.9% (<italic toggle="yes">n</italic>&#160;=&#160;460) of those with very high-dose use had a register-based diagnosis of benzodiazepine use disorder, i.e. ICD-10 diagnosis F13. The respective prevalence was 0.2% (<italic toggle="yes">n</italic>&#160;=&#160;80) among the low-dose-users and 1.4% (<italic toggle="yes">n</italic>&#160;=&#160;167) among the medium high-dose users. Supplementary Table 4 shows the timing of dose escalation more precisely, in every 0.5 years up to 5 years.
<fig position="float" id="fig02" fig-type="fig" orientation="portrait"><label>Fig. 2</label><caption><p>Cohort criteria.</p><p>DDDs, defined daily doses.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S2056472424007804_fig2.jpg"/></fig></p><p>Very high-dose use was more common among men compared with women (10.9% versus 4.6%, <italic toggle="yes">P</italic>&#160;&lt;&#160;0.001). Use of less than 0.5&#160;DDDs/day was more common among women, while very high-dose use of &#8805;3.5&#160;DDDs/day (based on the highest measured dose in any point of the follow-up period) was clearly more common among men compared with women (8.6% versus 3.6%). In the men's group, the dose was significantly higher (mean 1.24, s.d. 1.43) compared with the women's group (mean 0.83, s.d. 1.05).</p><p>The distribution of BZDR use in extremely high doses by gender and age is presented more closely in <xref rid="fig01" ref-type="fig">Fig. 1a</xref>. Associations between the first dispensed BZDR and BZDR combinations in extremely high-dose BZDR use are presented in <xref rid="fig01" ref-type="fig">Fig. 1b</xref> and in <xref rid="tab01" ref-type="table">Table 1</xref>. Initiating with two or more BZDRs, i.e. polypharmacy, was common in extremely high-dose BZDR use. Extremely high-dose BZDR use was clearly associated with initiating with clonazepam and alprazolam, and the most common combinations of BZDRs in extremely high-dose use were diazepam-temazepam and diazepam-zopiclone.
<table-wrap position="float" id="tab01" orientation="portrait"><label>Table 1</label><caption><p>Highest measured dose in defined daily doses per day and its associations to first dispensed benzodiazepines and related drugs</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S2056472424007804_tab1.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="center" colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th align="center" colspan="1" rowspan="1">%</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">Highest dose, anatomical therapeutic chemical classification system</td></tr><tr><td colspan="1" rowspan="1">Diazepam N05BA01</td><td colspan="1" rowspan="1">292</td><td colspan="1" rowspan="1">8.2</td></tr><tr><td colspan="1" rowspan="1">Oxazepam N05BA04</td><td colspan="1" rowspan="1">69</td><td colspan="1" rowspan="1">1.9</td></tr><tr><td colspan="1" rowspan="1">Alprazolam N05BA12</td><td colspan="1" rowspan="1">338</td><td colspan="1" rowspan="1">9.5</td></tr><tr><td colspan="1" rowspan="1">Zopiclone N05CF01</td><td colspan="1" rowspan="1">177</td><td colspan="1" rowspan="1">5.0</td></tr><tr><td colspan="1" rowspan="1">Zolpidem N05CF02</td><td colspan="1" rowspan="1">77</td><td colspan="1" rowspan="1">2.2</td></tr><tr><td colspan="1" rowspan="1">Temazepam N05CD07</td><td colspan="1" rowspan="1">85</td><td colspan="1" rowspan="1">2.4</td></tr><tr><td colspan="1" rowspan="1">Clonazepam N03AE01</td><td colspan="1" rowspan="1">372</td><td colspan="1" rowspan="1">10.5</td></tr><tr><td colspan="1" rowspan="1">Polypharmacy</td><td colspan="1" rowspan="1">2030</td><td colspan="1" rowspan="1">57.1</td></tr><tr><td colspan="3" rowspan="1">Most common two-drug combinations</td></tr><tr><td colspan="1" rowspan="1">Diazepam and Temazepam N05BA01, N05CD07</td><td colspan="1" rowspan="1">246</td><td colspan="1" rowspan="1">6.9</td></tr><tr><td colspan="1" rowspan="1">Diazepam and Zopiclone N05BA01, N05CF01</td><td colspan="1" rowspan="1">130</td><td colspan="1" rowspan="1">3.7</td></tr></tbody></table></alternatives></table-wrap></p><p>The associations between sociodemographic factors and BZDR dose group adjusted with gender, age, level of education, psychiatric disorders including SUD, and social benefits and disability pension status are presented in <xref rid="tab02" ref-type="table">Table 2</xref>. The mean age in the very high-dose user group was 36.9 (s.d. 12.76), in the medium high-dose user group 46.4 (s.d. 11.93) and in low-dose user group 47.3 (s.d. 11.65). Very high-dose use manifested clearly in younger age groups. Of the 18- to 25-year-olds, 25.4% had very high-dose use at some point of the 5-year follow-up.
<table-wrap position="float" id="tab02" orientation="portrait"><label>Table 2</label><caption><p>Associations between sociodemographic background, psychiatric morbidity and subsequent BZDR dose in a 5-year follow-up results of multinomial logistic regression analyses</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S2056472424007804_tab2.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="char" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="center" colspan="2" rowspan="1">Low dose (&lt;1.0 DDDs/day) <italic toggle="yes">n</italic>&#160;=&#160;32&#160;301</th><th align="center" colspan="2" rowspan="1">Medium high dose (1 to 3 DDDs/day) <italic toggle="yes">n</italic>&#160;=&#160;12&#160;266</th><th align="center" colspan="1" rowspan="1">Medium high dose versus low dose</th><th align="center" colspan="2" rowspan="1">Very high dose (&#8805;3.0 DDDs/day) <italic toggle="yes">n</italic>&#160;=&#160;3557</th><th align="center" colspan="1" rowspan="1">Very high dose versus low dose</th></tr><tr><th align="center" colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th align="center" colspan="1" rowspan="1">%</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th align="center" colspan="1" rowspan="1">%</th><th align="center" colspan="1" rowspan="1">Adjusted<xref rid="tfn2_2" ref-type="table-fn"><sup>a</sup></xref> odds ratio (95% CI)</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th align="center" colspan="1" rowspan="1">%</th><th align="center" colspan="1" rowspan="1">Adjusted<xref rid="tfn2_2" ref-type="table-fn"><sup>a</sup></xref> odds ratio (95% CI)</th></tr></thead><tbody><tr><td colspan="9" rowspan="1">Gender</td></tr><tr><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">12&#160;735</td><td colspan="1" rowspan="1">39.4</td><td colspan="1" rowspan="1">6311</td><td colspan="1" rowspan="1">51.5</td><td colspan="1" rowspan="1">1.47 (1.41&#8211;1.54)</td><td colspan="1" rowspan="1">2321</td><td colspan="1" rowspan="1">65.3</td><td colspan="1" rowspan="1">2.20 (2.04&#8211;2.38)</td></tr><tr><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">19&#160;566</td><td colspan="1" rowspan="1">60.6</td><td colspan="1" rowspan="1">5955</td><td colspan="1" rowspan="1">48.5</td><td align="center" colspan="1" rowspan="1">1.00/reference</td><td colspan="1" rowspan="1">1236</td><td colspan="1" rowspan="1">34.7</td><td align="center" colspan="1" rowspan="1">1.00/reference</td></tr><tr><td colspan="9" rowspan="1">Age category</td></tr><tr><td colspan="1" rowspan="1">18&#8211;25</td><td colspan="1" rowspan="1">2026</td><td colspan="1" rowspan="1">6.3</td><td colspan="1" rowspan="1">904</td><td colspan="1" rowspan="1">7.4</td><td colspan="1" rowspan="1">1.13 (1.02&#8211;1.24)</td><td colspan="1" rowspan="1">905</td><td colspan="1" rowspan="1">25.4</td><td colspan="1" rowspan="1">8.32 (7.15&#8211;9.68)</td></tr><tr><td colspan="1" rowspan="1">26&#8211;35</td><td colspan="1" rowspan="1">4254</td><td colspan="1" rowspan="1">13.2</td><td colspan="1" rowspan="1">1737</td><td colspan="1" rowspan="1">14.2</td><td colspan="1" rowspan="1">1.24 (1.15&#8211;1.34)</td><td colspan="1" rowspan="1">873</td><td colspan="1" rowspan="1">24.5</td><td colspan="1" rowspan="1">5.40 (4.68&#8211;6.23)</td></tr><tr><td colspan="1" rowspan="1">36&#8211;45</td><td colspan="1" rowspan="1">7082</td><td colspan="1" rowspan="1">21.9</td><td colspan="1" rowspan="1">2653</td><td colspan="1" rowspan="1">21.6</td><td colspan="1" rowspan="1">1.17 (1.09&#8211;1.24)</td><td colspan="1" rowspan="1">766</td><td colspan="1" rowspan="1">21.5</td><td colspan="1" rowspan="1">3.19 (2.77&#8211;3.67)</td></tr><tr><td colspan="1" rowspan="1">46&#8211;55</td><td colspan="1" rowspan="1">9801</td><td colspan="1" rowspan="1">30.5</td><td colspan="1" rowspan="1">3743</td><td colspan="1" rowspan="1">30.5</td><td colspan="1" rowspan="1">1.14 (1.08&#8211;1.21)</td><td colspan="1" rowspan="1">668</td><td colspan="1" rowspan="1">18.8</td><td colspan="1" rowspan="1">1.96 (1.70&#8211;2.25)</td></tr><tr><td colspan="1" rowspan="1">56&#8211;65</td><td colspan="1" rowspan="1">9138</td><td colspan="1" rowspan="1">28.3</td><td colspan="1" rowspan="1">3229</td><td colspan="1" rowspan="1">26.3</td><td align="center" colspan="1" rowspan="1">1.00/reference</td><td colspan="1" rowspan="1">345</td><td colspan="1" rowspan="1">9.7</td><td align="center" colspan="1" rowspan="1">1.00/reference</td></tr><tr><td colspan="9" rowspan="1">Education</td></tr><tr><td colspan="1" rowspan="1">Primary school or less</td><td colspan="1" rowspan="1">8743</td><td colspan="1" rowspan="1">27.1</td><td colspan="1" rowspan="1">4446</td><td colspan="1" rowspan="1">36.2</td><td align="center" colspan="1" rowspan="1">1.00/reference</td><td colspan="1" rowspan="1">1842</td><td colspan="1" rowspan="1">51.8</td><td align="center" colspan="1" rowspan="1">1.00/reference</td></tr><tr><td colspan="1" rowspan="1">High school/technical school</td><td colspan="1" rowspan="1">18195</td><td colspan="1" rowspan="1">56.3</td><td colspan="1" rowspan="1">6565</td><td colspan="1" rowspan="1">53.5</td><td colspan="1" rowspan="1">0.79 (0.76&#8211;0.83)</td><td colspan="1" rowspan="1">1526</td><td colspan="1" rowspan="1">42.9</td><td colspan="1" rowspan="1">0.53 (0.48&#8211;0.57)</td></tr><tr><td colspan="1" rowspan="1">University</td><td colspan="1" rowspan="1">5363</td><td colspan="1" rowspan="1">16.6</td><td colspan="1" rowspan="1">1255</td><td colspan="1" rowspan="1">10.2</td><td colspan="1" rowspan="1">0.61 (0.56&#8211;0.65)</td><td colspan="1" rowspan="1">189</td><td colspan="1" rowspan="1">5.3</td><td colspan="1" rowspan="1">0.32 (0.27&#8211;0.38)</td></tr><tr><td colspan="9" rowspan="1">Occupation</td></tr><tr><td colspan="1" rowspan="1">Managerial/professional</td><td colspan="1" rowspan="1">8761</td><td colspan="1" rowspan="1">27.1</td><td colspan="1" rowspan="1">2063</td><td colspan="1" rowspan="1">16.8</td><td align="center" colspan="1" rowspan="1">1.00/reference</td><td colspan="1" rowspan="1">337</td><td colspan="1" rowspan="1">9.5</td><td align="center" colspan="1" rowspan="1">1.00/reference</td></tr><tr><td colspan="1" rowspan="1">office worker</td><td colspan="1" rowspan="1">2029</td><td colspan="1" rowspan="1">6.3</td><td colspan="1" rowspan="1">521</td><td colspan="1" rowspan="1">4.2</td><td colspan="1" rowspan="1">1.09 (0.98&#8211;1.21)</td><td colspan="1" rowspan="1">86</td><td colspan="1" rowspan="1">2.4</td><td colspan="1" rowspan="1">1.10 (0.87&#8211;1.40)</td></tr><tr><td colspan="1" rowspan="1">Farming/forestry</td><td colspan="1" rowspan="1">460</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">144</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">1.33 (1.10&#8211;1.61)</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">0.5</td><td colspan="1" rowspan="1">1.01 (0.63&#8211;1.65)</td></tr><tr><td colspan="1" rowspan="1">Sales/industry/cleaning/other</td><td colspan="1" rowspan="1">8337</td><td colspan="1" rowspan="1">25.8</td><td colspan="1" rowspan="1">2770</td><td colspan="1" rowspan="1">22.6</td><td colspan="1" rowspan="1">1.41 (1.32&#8211;1.51)</td><td colspan="1" rowspan="1">675</td><td colspan="1" rowspan="1">19.0</td><td colspan="1" rowspan="1">2.11 (1.84&#8211;2.41)</td></tr><tr><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1">12&#160;714</td><td colspan="1" rowspan="1">39.4</td><td colspan="1" rowspan="1">6768</td><td colspan="1" rowspan="1">55.2</td><td colspan="1" rowspan="1">2.26 (2.14&#8211;2.39)</td><td colspan="1" rowspan="1">2441</td><td colspan="1" rowspan="1">68.6</td><td colspan="1" rowspan="1">4.99 (4.44&#8211;5.61)</td></tr><tr><td colspan="1" rowspan="1">Social benefits<xref rid="tfn2_3" ref-type="table-fn"><sup>b</sup></xref></td><td colspan="1" rowspan="1">8842</td><td colspan="1" rowspan="1">27.4</td><td colspan="1" rowspan="1">5281</td><td colspan="1" rowspan="1">43.1</td><td colspan="1" rowspan="1">1.49 (1.42&#8211;1.57)</td><td colspan="1" rowspan="1">2233</td><td colspan="1" rowspan="1">62.8</td><td colspan="1" rowspan="1">1.91 (1.76&#8211;2.08)</td></tr><tr><td colspan="1" rowspan="1">Disability pension</td><td colspan="1" rowspan="1">4358</td><td colspan="1" rowspan="1">13.5</td><td colspan="1" rowspan="1">2690</td><td colspan="1" rowspan="1">21.9</td><td colspan="1" rowspan="1">1.50 (1.42&#8211;1.57)</td><td colspan="1" rowspan="1">565</td><td colspan="1" rowspan="1">15.9</td><td colspan="1" rowspan="1">1.65 (1.48&#8211;1.84)</td></tr><tr><td colspan="9" rowspan="1">Psychiatric comorbidity</td></tr><tr><td colspan="1" rowspan="1">Schizophrenia</td><td colspan="1" rowspan="1">1324</td><td colspan="1" rowspan="1">4.1</td><td colspan="1" rowspan="1">1099</td><td colspan="1" rowspan="1">9.0</td><td colspan="1" rowspan="1">1.48 (1.35&#8211;1.62)</td><td colspan="1" rowspan="1">349</td><td colspan="1" rowspan="1">9.8</td><td colspan="1" rowspan="1">1.05 (0.92&#8211;1.21)</td></tr><tr><td colspan="1" rowspan="1">Bipolar disorder</td><td colspan="1" rowspan="1">486</td><td colspan="1" rowspan="1">1.5</td><td colspan="1" rowspan="1">358</td><td colspan="1" rowspan="1">2.9</td><td colspan="1" rowspan="1">1.35 (1.17&#8211;1.56)</td><td colspan="1" rowspan="1">130</td><td colspan="1" rowspan="1">3.7</td><td colspan="1" rowspan="1">1.33 (1.07&#8211;1.65)</td></tr><tr><td colspan="1" rowspan="1">Depression</td><td colspan="1" rowspan="1">2323</td><td colspan="1" rowspan="1">7.2</td><td colspan="1" rowspan="1">1372</td><td colspan="1" rowspan="1">11.2</td><td colspan="1" rowspan="1">1.24 (1.15&#8211;1.33)</td><td colspan="1" rowspan="1">390</td><td colspan="1" rowspan="1">11.0</td><td colspan="1" rowspan="1">0.97 (0.88&#8211;1.13)</td></tr><tr><td colspan="1" rowspan="1">Attention-deficit hyperactivity disorder</td><td colspan="1" rowspan="1">63</td><td colspan="1" rowspan="1">0.2</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1">1.36 (0.92&#8211;2.02)</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">1.17 (0.71&#8211;1.93)</td></tr><tr><td colspan="1" rowspan="1">Substance use disorder</td><td colspan="1" rowspan="1">934</td><td colspan="1" rowspan="1">2.9</td><td colspan="1" rowspan="1">1040</td><td colspan="1" rowspan="1">8.5</td><td colspan="1" rowspan="1">1.81 (1.64&#8211;1.99)</td><td colspan="1" rowspan="1">639</td><td colspan="1" rowspan="1">18.0</td><td colspan="1" rowspan="1">3.20 (2.84&#8211;3.62)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="tfn2_1" fn-type="other"><p>BZDR, benzodiazepines and related drugs; DDDs, defined daily doses.</p></fn><fn id="tfn2_2" fn-type="other"><label>a.</label><p>Gender, age, level of education, psychiatric disorders including substance use disorder, and social benefits and disability pension status were used as covariates. <italic toggle="yes">n</italic>&#160;=&#160;48&#160;124.</p></fn><fn id="tfn2_3" fn-type="other"><label>b.</label><p>Receipt of social benefits, including basic social assistance, labour market subsidy, basic unemployment allowance, national pension and study grants, maternity allowance, paternity allowance, parental allowance and child home care allowance during the year 2005.</p></fn></table-wrap-foot></table-wrap></p><p>Both medium high-dose and very high-dose BZDR use were associated with a lower level of education. This was evident for the very high-dose users in particular: 51.8% had completed only primary and lower secondary education. The respective figures for medium high-dose users and low-dose users were 36.2 and 27.1%. As for the occupational information, the number of persons with unknown profession information was notable. Compared with low-dose BZDR use, social benefits and being on disability pension were more common among medium high-dose and very high-dose BZDR users. In total, 62.8% of the very high-dose users received social benefits, and 15.8% were on disability pension.</p><p>As seen in <xref rid="tab02" ref-type="table">Table 2</xref>, the psychiatric conditions most commonly associated with very high-dose BZDR use were SUD, depression and schizophrenia. Compared with low-dose use, the risk for very high-dose use was elevated also among BZDR users who were diagnosed with either bipolar disorder or attention-deficit hyperactivity disorder.</p><p>Antidepressant and BZDR combinations are presented in Supplementary Table 3. The prevalence of antidepressant use was 22.9% among low-dose users, 30.0% medium high-dose users and 34.6% among very high-dose users, medium high-dose versus low-dose odds ratio (95% CI) 1.44 (1.38&#8211;1.51) and very high-dose versus low-dose odds ratio (95% CI) 1.78 (1.65&#8211;1.91).</p><p>All SUDs were associated with an increased risk for both medium high-dose and very high-dose use of BZDRs, the associations being more pronounced for very high-dose BZDR use. Compared with low-dose BZDR use, very high-dose use was more prevalent among incident BZDR users with a polysubstance use disorder diagnosis (ICD-10 code F19) (0.2% versus 6.8%; odds ratio&#160;=&#160;30.78, 95% CI&#160;=&#160;23.32&#8211;40.63; data not shown in tables). Previous diagnosis of substance misuse was defined as ICD-10 diagnoses from F10 to F19 and are seen in more detail in Supplementary Table 2.</p><p>Associations between BZDR use and the first BZDR prescriber are presented in <xref rid="tab03" ref-type="table">Table 3</xref>. BZDRs were mostly initiated by general medicine physicians or those with no specialty, with the total of 26&#160;001 (54.0% of) cases. However, compared with general medicine/no specialty practitioners, the risk for very high-dose BZDR use was the highest among those with a psychiatrist as the first prescriber, and the risk decreased if the prescriber was a neurologist or occupational medicine physician. In the medium high-dose user group, however, the prescriber was most commonly either a psychiatrist or a neurologist.
<table-wrap position="float" id="tab03" orientation="portrait"><label>Table 3</label><caption><p>Associations between the incident prescribers&#8217; specialty and subsequent BZDR dose &#8211; results of multinomial logistic regression analyses</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S2056472424007804_tab3.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="char" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="center" colspan="2" rowspan="1">Low dose (&lt;1.0&#160;DDDs/day) <italic toggle="yes">n</italic>&#160;=&#160;32&#160;301</th><th align="center" colspan="2" rowspan="1">Medium high dose (1 to 3&#160;DDDs/day) <italic toggle="yes">n</italic>&#160;=&#160;12&#160;266</th><th align="center" colspan="1" rowspan="1">Medium high dose versus low dose</th><th align="center" colspan="2" rowspan="1">Very high dose (&#8805;3.0&#160;DDDs/day) <italic toggle="yes">n</italic>&#160;=&#160;3557</th><th align="center" colspan="1" rowspan="1">Very high dose versus low dose</th></tr><tr><th align="left" colspan="1" rowspan="1">Prescriber's specialty</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th align="center" colspan="1" rowspan="1">%</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th align="center" colspan="1" rowspan="1">%</th><th align="center" colspan="1" rowspan="1">Adjusted<xref rid="tfn3_2" ref-type="table-fn"><sup>a</sup></xref> odds ratio (95% CI)</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th align="center" colspan="1" rowspan="1">%</th><th align="center" colspan="1" rowspan="1">Adjusted<xref rid="tfn3_2" ref-type="table-fn"><sup>a</sup></xref> odds ratio (95% CI)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Neurology</td><td colspan="1" rowspan="1">823</td><td colspan="1" rowspan="1">63.4</td><td colspan="1" rowspan="1">419</td><td colspan="1" rowspan="1">32.3</td><td colspan="1" rowspan="1">1.35 (1.20&#8211;1.53)</td><td colspan="1" rowspan="1">57</td><td colspan="1" rowspan="1">4.4</td><td colspan="1" rowspan="1">0.59 (0.45&#8211;0.77)</td></tr><tr><td colspan="1" rowspan="1">Psychiatry</td><td colspan="1" rowspan="1">3642</td><td colspan="1" rowspan="1">57.0</td><td colspan="1" rowspan="1">2057</td><td colspan="1" rowspan="1">32.2</td><td colspan="1" rowspan="1">1.50 (1.41&#8211;1.60)</td><td colspan="1" rowspan="1">687</td><td colspan="1" rowspan="1">10.8</td><td colspan="1" rowspan="1">1.60 (1.46&#8211;1.76)</td></tr><tr><td colspan="1" rowspan="1">Occupational medicine</td><td colspan="1" rowspan="1">4146</td><td colspan="1" rowspan="1">77.0</td><td colspan="1" rowspan="1">1023</td><td colspan="1" rowspan="1">19.0</td><td colspan="1" rowspan="1">0.66 (0.61&#8211;0.71)</td><td colspan="1" rowspan="1">218</td><td colspan="1" rowspan="1">4.0</td><td colspan="1" rowspan="1">0.45 (0.39&#8211;0.52)</td></tr><tr><td colspan="1" rowspan="1">General medicine/No specialty</td><td colspan="1" rowspan="1">17&#160;406</td><td colspan="1" rowspan="1">66.9</td><td colspan="1" rowspan="1">6543</td><td colspan="1" rowspan="1">25.2</td><td align="center" colspan="1" rowspan="1">1.00/reference</td><td colspan="1" rowspan="1">2052</td><td colspan="1" rowspan="1">7.9</td><td align="center" colspan="1" rowspan="1">1.00/reference</td></tr><tr><td colspan="1" rowspan="1">Other specialty</td><td colspan="1" rowspan="1">6284</td><td colspan="1" rowspan="1">69.4</td><td colspan="1" rowspan="1">2224</td><td colspan="1" rowspan="1">24.6</td><td colspan="1" rowspan="1">0.94 (0.89&#8211;1.00)</td><td colspan="1" rowspan="1">543</td><td colspan="1" rowspan="1">6.0</td><td colspan="1" rowspan="1">0.73 (0.66&#8211;0.81)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="tfn3_1" fn-type="other"><p>BZDR, benzodiazepines and related drugs; DDDs, defined daily doses.</p></fn><fn id="tfn3_2" fn-type="other"><label>a.</label><p>Gender, age, level of education, psychiatric comorbidity including substance use disorder, and social benefits and disability pension status were used as covariates. <italic toggle="yes">n</italic>&#160;=&#160;48&#160;124.</p></fn></table-wrap-foot></table-wrap></p><p><xref rid="tab04" ref-type="table">Table 4</xref> presents the associations between the active BZDR substance and subsequent BZDR dose. In all dose groups, the BZDRs most commonly purchased first were zopiclone, followed by zolpidem and oxazepam in the low-dose and medium high-dose groups. Among those who initiated with polypharmacy, i.e. initiated with more than one BZDR, 23.4% used BZDR in very high doses at some point in the 5-year follow-up period. With clonazepam initiation, 17.9% of the overall use was in the very high-dose group. With diazepam and alprazolam initiations, the figures were 13.6 and 12.5%, respectively.
<table-wrap position="float" id="tab04" orientation="portrait"><label>Table 4</label><caption><p>Associations between first dispensed benzodiazepine and subsequent BZDR dose. Results of multinomial logistic regression analyses</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S2056472424007804_tab4.jpg"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="center" colspan="2" rowspan="1">Low dose (&lt;1.0&#160;DDDs/day) <italic toggle="yes">n</italic>&#160;=&#160;32&#160;301</th><th align="center" colspan="2" rowspan="1">Medium high dose (1 to 3&#160;DDDs/day) <italic toggle="yes">n</italic>&#160;=&#160;12&#160;266</th><th align="center" colspan="2" rowspan="1">Medium high dose versus low dose</th><th align="center" colspan="2" rowspan="1">Very high dose (&#8805;3.0&#160;DDDs/day) <italic toggle="yes">n</italic>&#160;=&#160;3557</th><th align="center" colspan="2" rowspan="1">Very high dose versus low dose</th></tr><tr><th align="left" colspan="1" rowspan="1">First dispensed BZDR</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th align="center" colspan="1" rowspan="1">%</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th align="center" colspan="1" rowspan="1">%</th><th align="center" colspan="1" rowspan="1">Odds ratio (95% C I)</th><th align="center" colspan="1" rowspan="1">Adjusted<xref rid="tfn4_2" ref-type="table-fn"><sup>a</sup></xref> odds ratio (95% CI)</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th align="center" colspan="1" rowspan="1">%</th><th align="center" colspan="1" rowspan="1">Odds ratio (95% CI)</th><th align="center" colspan="1" rowspan="1">Adjusted<xref rid="tfn4_2" ref-type="table-fn"><sup>a</sup></xref> odds<break/>ratio (95% CI)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Oxazepam</td><td colspan="1" rowspan="1">5365</td><td colspan="1" rowspan="1">73.3</td><td colspan="1" rowspan="1">1463</td><td colspan="1" rowspan="1">20.0</td><td align="center" colspan="1" rowspan="1">reference</td><td align="center" colspan="1" rowspan="1">reference</td><td colspan="1" rowspan="1">495</td><td colspan="1" rowspan="1">6.8</td><td align="center" colspan="1" rowspan="1">reference</td><td align="center" colspan="1" rowspan="1">reference</td></tr><tr><td colspan="1" rowspan="1">Clonazepam</td><td colspan="1" rowspan="1">805</td><td colspan="1" rowspan="1">47.5</td><td colspan="1" rowspan="1">588</td><td colspan="1" rowspan="1">34.7</td><td colspan="1" rowspan="1">2.68 (2.37&#8211;3.02)</td><td colspan="1" rowspan="1">2.69 (2.38&#8211;3.04)</td><td colspan="1" rowspan="1">303</td><td colspan="1" rowspan="1">17.9</td><td colspan="1" rowspan="1">4.08 (3.47&#8211;4.79)</td><td colspan="1" rowspan="1">3.86 (3.24&#8211;4.60)</td></tr><tr><td colspan="1" rowspan="1">Diazepam</td><td colspan="1" rowspan="1">2158</td><td colspan="1" rowspan="1">55.0</td><td colspan="1" rowspan="1">1233</td><td colspan="1" rowspan="1">31.4</td><td colspan="1" rowspan="1">2.10 (1.91&#8211;2.29)</td><td colspan="1" rowspan="1">1.83 (1.67&#8211;2.01)</td><td colspan="1" rowspan="1">533</td><td colspan="1" rowspan="1">13.6</td><td colspan="1" rowspan="1">2.68 (2.35&#8211;3.06)</td><td colspan="1" rowspan="1">2.05 (1.78&#8211;2.36)</td></tr><tr><td colspan="1" rowspan="1">Temazepam</td><td colspan="1" rowspan="1">1387</td><td colspan="1" rowspan="1">54.6</td><td colspan="1" rowspan="1">961</td><td colspan="1" rowspan="1">37.8</td><td colspan="1" rowspan="1">2.54 (2.30&#8211;2.81)</td><td colspan="1" rowspan="1">2.54 (2.29&#8211;2.82)</td><td colspan="1" rowspan="1">193</td><td colspan="1" rowspan="1">7.6</td><td colspan="1" rowspan="1">1.51 (1.26&#8211;1.80)</td><td colspan="1" rowspan="1">2.05 (1.70&#8211;2.47)</td></tr><tr><td colspan="1" rowspan="1">Alprazolam</td><td colspan="1" rowspan="1">2539</td><td colspan="1" rowspan="1">66.9</td><td colspan="1" rowspan="1">783</td><td colspan="1" rowspan="1">20.6</td><td colspan="1" rowspan="1">1.13 (1.03&#8211;1.25)</td><td colspan="1" rowspan="1">1.27 (1.15&#8211;1.41)</td><td colspan="1" rowspan="1">474</td><td colspan="1" rowspan="1">12.5</td><td colspan="1" rowspan="1">2.02 (1.77&#8211;2.32)</td><td colspan="1" rowspan="1">1.76 (1.52&#8211;2.03)</td></tr><tr><td colspan="1" rowspan="1">Zopiclone</td><td colspan="1" rowspan="1">10&#160;953</td><td colspan="1" rowspan="1">70.7</td><td colspan="1" rowspan="1">3889</td><td colspan="1" rowspan="1">25.1</td><td colspan="1" rowspan="1">1.30 (1.22&#8211;1.39)</td><td colspan="1" rowspan="1">1.50 (1.39&#8211;1.61)</td><td colspan="1" rowspan="1">656</td><td colspan="1" rowspan="1">4.2</td><td colspan="1" rowspan="1">0.65 (0.58&#8211;0.73)</td><td colspan="1" rowspan="1">0.89 (0.78&#8211;1.01)</td></tr><tr><td colspan="1" rowspan="1">Zolpidem</td><td colspan="1" rowspan="1">6970</td><td colspan="1" rowspan="1">76.9</td><td colspan="1" rowspan="1">1745</td><td colspan="1" rowspan="1">19.3</td><td colspan="1" rowspan="1">0.92 (0.85&#8211;0.99)</td><td colspan="1" rowspan="1">1.16 (1.07&#8211;1.26)</td><td colspan="1" rowspan="1">344</td><td colspan="1" rowspan="1">3.8</td><td colspan="1" rowspan="1">0.54 (0.46&#8211;0.62)</td><td colspan="1" rowspan="1">0.78 (0.67&#8211;0.90)</td></tr><tr><td colspan="1" rowspan="1">All others</td><td colspan="1" rowspan="1">1549</td><td colspan="1" rowspan="1">52.8</td><td colspan="1" rowspan="1">1144</td><td colspan="1" rowspan="1">39.0</td><td colspan="1" rowspan="1">2.70 (2.46&#8211;2.98)</td><td colspan="1" rowspan="1">2.69 (2.43&#8211;2.96)</td><td colspan="1" rowspan="1">243</td><td colspan="1" rowspan="1">8.3</td><td colspan="1" rowspan="1">1.70 (1.44&#8211;2.00)</td><td colspan="1" rowspan="1">1.68 (1.41&#8211;2.00)</td></tr><tr><td colspan="1" rowspan="1">Polypharmacy</td><td colspan="1" rowspan="1">575</td><td colspan="1" rowspan="1">42.6</td><td colspan="1" rowspan="1">460</td><td colspan="1" rowspan="1">34.0</td><td colspan="1" rowspan="1">2.93 (2.56-3.36)</td><td colspan="1" rowspan="1">2.80 (2.44&#8211;3.22)</td><td colspan="1" rowspan="1">316</td><td colspan="1" rowspan="1">23.4</td><td colspan="1" rowspan="1">5.96 (5.05&#8211;7.03)</td><td colspan="1" rowspan="1">5.11 (4.27&#8211;6.12)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="tfn4_1" fn-type="other"><p>BZDR, benzodiazepines and related drugs; DDDs, defined daily doses.</p></fn><fn id="tfn4_2" fn-type="other"><label>a.</label><p>Gender, age, level of education, psychiatric comorbidity including substance use disorder, and social benefits and disability pension status were used as covariates. <italic toggle="yes">n</italic>&#160;=&#160;48&#160;124.</p></fn></table-wrap-foot></table-wrap></p><p>Compared with oxazepam, initiating BZDR use with clonazepam, diazepam or alprazolam was associated with an increased risk for very high-dose BZDR use. This was evident also after adjustments for gender, age, level of education, psychiatric disorders including SUD, and social benefits and disability pension status.</p></sec></sec><sec sec-type="discussion" id="sec3"><title>Discussion</title><p>The harmful consequences and adverse effects of inadequate high-dose BZDR use, such as cognitive and memory impairment, increased risk of trauma and other accidents, and the risk of tolerance and use disorder, as well as lower quality of life, have been shown in many studies.<sup><xref rid="ref22" ref-type="bibr">22</xref></sup> Our findings, utilising national data on all reimbursed prescription drug purchases in Finland, indicate that a high proportion, up to 10% of young men using BZDRs end up using them in very high doses periodically, i.e. &#8805;3.0&#160;DDDs/day. Initiating BZDR use with clonazepam, diazepam or alprazolam associates with an increased risk for very high-dose use, compared with initiating BZDR use with oxazepam. In all, 58% of very high-dose use occurred in BZDR users who received their first prescription from general practitioners. These findings underline that careful consideration should be taken when initiating these medications.</p><sec sec-type="other" id="sec3-1"><title>Risk for BZDR dose escalation: psychiatric disorders and clinical factors</title><p>When initiating BZDRs, certain risk factors should be evaluated. Our results emphasise previous findings<sup><xref rid="ref6" ref-type="bibr">6</xref></sup> suggesting that especially being male and young age, having a lower level of education and psychiatric disorders including SUD, associate with an increased risk for very high-dose BZDR use, although using BZDRs in general seems to be common in all age groups and genders.<sup><xref rid="ref3" ref-type="bibr">3</xref>,<xref rid="ref22" ref-type="bibr">22</xref>,<xref rid="ref23" ref-type="bibr">23</xref></sup></p><p>We found that bipolar disorder and SUD were most associated with very high-dose use of BZDRs compared with low-dose use. All psychiatric conditions except ADHD were associated with very high-dose use. Although BZDRs have their place in the short-term management of, for example, anxiety, psychotic symptoms and alcohol withdrawal, the available evidence does not support long-term or high-dose BZDR use.<sup><xref rid="ref24" ref-type="bibr">24</xref>,<xref rid="ref25" ref-type="bibr">25</xref></sup> On the contrary, very high-dose BZDR use has been associated with, for example, neurological and systemic adverse effects in people with schizophrenia<sup><xref rid="ref26" ref-type="bibr">26</xref></sup> and also adverse effects in treating depression<sup><xref rid="ref27" ref-type="bibr">27</xref></sup> and anxiety.<sup><xref rid="ref28" ref-type="bibr">28</xref></sup> In addition, although some previous studies suggest that benzodiazepine misuse is not exclusive to SUD populations,<sup><xref rid="ref29" ref-type="bibr">29</xref></sup> we found that all specific SUDs were associated with an increased risk for both medium high-dose and very high-dose use of BZDRs.</p><p>Our study shows that the largest group, 58% of very high-dose use, occurred with BZDR users who received their first prescription from general practitioners. In addition, compared with other specialties, psychiatrists seemed to be more likely to initiate BZDR treatment resulting in very high-dose BZDR use. As many psychiatric conditions have been traditionally treated with BZDRs,<sup><xref rid="ref30" ref-type="bibr">30</xref></sup> this seems logical. Acknowledging this, paying attention to current guidelines<sup><xref rid="ref31" ref-type="bibr">31</xref></sup> seems extremely important for preventing long-term use and dose escalation in the future.<sup><xref rid="ref32" ref-type="bibr">32</xref></sup> To help clinicians avoid these unwanted results, guidelines and recommendations, such as &#8216;Smart to avoid recommendations&#8217; (in Finnish) and &#8216;Do not do recommendations&#8217; from the National Institute for Health and Care Excellence (NICE), have instructions to not routinely offer benzodiazepines to treat, for example, social anxiety disorder in adults, and have been revised recently.</p></sec><sec sec-type="other" id="sec3-2"><title>Risk for BZDR dose escalation: choice of initial BZDR</title><p>According to our findings, initiating BZDR use with oxazepam possesses a lower risk for dose escalation compared with diazepam, alprazolam and clonazepam. Alprazolam and diazepam, which are high-potency and quickly eliminating BZDRs, potentially cause more severe withdrawal syndrome than other BZDRs when trying to give up the medication. Diazepam and alprazolam have known misuse potential, and they are commonly available in illegal markets.<sup><xref rid="ref33" ref-type="bibr">33</xref></sup> Although clonazepam has a long elimination half-life,<sup><xref rid="ref34" ref-type="bibr">34</xref></sup> it is a high-potency BZDR like diazepam and alprazolam. In our study, clonazepam is also associated with increased risk for very high-dose use compared with oxazepam. Our findings add to the previous but limited clonazepam studies indicating that also clonazepam users have a high risk of developing long-term BZDR use and dose escalation.<sup><xref rid="ref7" ref-type="bibr">7</xref></sup> Clonazepam also possesses a misuse risk<sup><xref rid="ref35" ref-type="bibr">35</xref></sup> and can, alone or in combination with other psychoactive substances, lead to adverse outcomes, such as cognitive impairment and aggravation of many psychiatric disorders.<sup><xref rid="ref36" ref-type="bibr">36</xref></sup></p></sec></sec><sec sec-type="other" id="sec4"><title>Strengths and limitations</title><p>The main strength of our study is that it has good generalisability, as it included a large nationwide cohort of adults initiating BZDR use. BZDR prescribing policies (and addictions overall) have varied and spread out in the past years, but the problems related to these medications are still, to a somewhat large extent, the same as in 2006&#8211;2011. However, this may affect the data and can be considered as something of a limitation. Our classification of BZDRs included the whole range of benzodiazepine-related substances and correlating factors, which has not been explored previously to this extent. In addition, the information sources and study population as well as the utilised methods (such as PRE2DUP) in our study are quite unique and comprehensive because of the Social Insurance Institution's register data and the advanced Finnish healthcare system.</p><p>Using prescription registers as the data source also has its limitations. The actual indications for BZDR use except epilepsy were lacking. When it comes to very high-dose use and specifically inadequate use of BZDRs, medications can also be bought from illegal markets without a doctor's prescription.<sup><xref rid="ref4" ref-type="bibr">4</xref>,<xref rid="ref14" ref-type="bibr">14</xref>,<xref rid="ref37" ref-type="bibr">37</xref>,<xref rid="ref38" ref-type="bibr">38</xref></sup> Hence, our information on the actual amounts of BZDRs used is not entirely comprehensive. The fact that some smaller packages are not reimbursed also affects adversely the data coverage. The correlation of a medication's actual use and its purchase is also questionable, but as some studies show, this is a minor concern.<sup><xref rid="ref39" ref-type="bibr">39</xref></sup></p><p>Certain diagnoses, especially those related to anxiety and substance use, can be somewhat underreported and underdiagnosed among clinicians and, therefore, these estimates may be misleadingly low as we lacked data from primary care. Clinical experience suggests that these comorbidities are much more common than our study suggests.<sup><xref rid="ref40" ref-type="bibr">40</xref></sup> The fact that the exact indications of prescribed BZDRs were not available may also cause some inaccuracies.</p></sec><sec sec-type="conclusions" id="sec5"><title>Conclusions</title><p>Our findings from this nationwide register-linkage study implicate that using benzodiazepines above the recommended dose is alarmingly common among people continuing benzodiazepine use after the first BZDR medication purchase. Although BZDRs have many useful qualities in clinical use, their adverse effects relating to high-dose use are indisputable. Certain subgroups, such as young male individuals with comorbid SUD, should be specially noticed as a potentially risky subgroup. Clinicians should be aware of the risk for dose escalation when initiating BZDR use with diazepam, alprazolam or clonazepam. Our findings also suggest favouring oxazepam over the aforementioned BZDRs.</p></sec><sec sec-type="supplementary-material" id="sec6"><title>Supporting information</title><supplementary-material id="sm01" position="float" content-type="local-data" orientation="portrait"><caption><title>S&#228;rkil&#228; et al. supplementary material</title><p>S&#228;rkil&#228; et al. supplementary material</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="S2056472424007804sup001.docx" id="d67e1662" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><sec sec-type="supplementary-material" id="nts1"><title>Supplementary material</title><p>Supplementary material is available online at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1192/bjo.2024.780">https://doi.org/10.1192/bjo.2024.780</uri></p></sec><sec sec-type="data-availability" id="sec-das1"><title>Data availability</title><p>H.S. and H.T. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The data that support the findings of this study are available from the Finnish government agencies, but restrictions apply to the availability of these data, which were used under licence for the current study and so are not publicly available.</p></sec><sec sec-type="other" id="sec-nts1"><title>Author contributions</title><p>Concept and design: all authors. Acquisition, analysis or interpretation of data: H.S., H.T., A.T., T.T., J.T., R.S., L.S. and J.H. Drafting of the manuscript: H.S., H.T., A.T., T.K., T.T., S.N. and J.H. Critical revision of the manuscript for important intellectual content: H.S., H.T., S.N., J.H., T.K., J.T., R.S., J.H. and T.T. Statistical analysis: H.S., H.T. and A.T. Funding obtained: H.S. and J.H. Administrative, technical or material support: H.T., A.T., T.K., L.S., R.S. and J.H. Supervision: S.N., J.H. and H.T.</p></sec><sec sec-type="funding-statement" id="sec-fs1"><title>Funding</title><p>This study was funded by a grant from The Finnish Foundation for Alcohol Studies, Turku Psychiatric services (grant 603459) and Turku University Hospital (grant P3704). The funders had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review and approval of the manuscript; or the decision to submit the manuscript for publication.</p></sec><sec sec-type="COI-statement" id="sec-ci1"><title>Declaration of interest</title><p>H.S. reported receiving personal fees from Duodecim, HUS Psychiatry, the Finnish Association for Substance Abuse Prevention, and the Finnish Society of Addiction Medicine. H.T., A.T. and J.T. reported participating in research projects funded by grants from Janssen-Cilag and Eli Lilly to their employing institution outside the submitted work. H.T. reported receiving grants and personal fees from Gedeon Richter, Janssen, Lundbeck and Otsuka. T.T. reported receiving personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Efeko, Eisai, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Nexstim, Orion, Pfizer, Schering-Plough and UCB. J.T. reported receiving lecture fees from Eli Lilly, Evidera, Janssen-Cilag, Lundbeck, Otsuka, Mediuutiset, Sidera and Sunovion outside the submitted work and is a consultant to HLS Therapeutics, Orion and WebMed Global. L.S. reported receiving grants from the Social Insurance Institution of Finland outside the submitted work. S.N. reported personal fees from Lundbeck and Shire-Takeda outside the submitted work. J.H. reported receiving research grants from the Social Insurance Institution of Finland and personal fees from Lundbeck, Orion and Otsuka during the conduct of the study. No other disclosures were reported.</p></sec><ref-list id="reflist1" content-type="normal"><title>References</title><ref id="ref1"><label>1</label><mixed-citation publication-type="journal" id="cite1"><string-name name-style="western"><surname>Nielsen</surname><given-names>S</given-names></string-name>. <article-title>Benzodiazepines</article-title>. <source>Curr Top Behav Neurosci</source><year>2017</year>; <volume>34</volume>: <fpage>141</fpage>&#8211;59.<pub-id pub-id-type="pmid">26695165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/7854_2015_425</pub-id></mixed-citation></ref><ref id="ref2"><label>2</label><mixed-citation publication-type="journal" id="cite2"><string-name name-style="western"><surname>Peng</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Morford</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Levander</surname><given-names>XA</given-names></string-name>. <article-title>Benzodiazepines and related sedatives</article-title>. <source>Med Clin North Am</source><year>2022</year>; <volume>106</volume>(<issue>1</issue>): <fpage>113</fpage>&#8211;29.<pub-id pub-id-type="pmid">34823725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcna.2021.08.012</pub-id></mixed-citation></ref><ref id="ref3"><label>3</label><mixed-citation publication-type="journal" id="cite3"><string-name name-style="western"><surname>Kurko</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Saastamoinen</surname><given-names>LK</given-names></string-name>, <string-name name-style="western"><surname>Tahkapaa</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tuulio-Henriksson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Taiminen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tiihonen</surname><given-names>J</given-names></string-name>, <etal>et al.</etal><article-title>Long-term use of benzodiazepines: definitions, prevalence and usage patterns &#8211; a systematic review of register-based studies</article-title>. <source>Eur Psychiatry</source><year>2015</year>; <volume>30</volume>(<issue>8</issue>): <fpage>1037</fpage>&#8211;47.<pub-id pub-id-type="pmid">26545257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eurpsy.2015.09.003</pub-id></mixed-citation></ref><ref id="ref4"><label>4</label><mixed-citation publication-type="journal" id="cite4"><string-name name-style="western"><surname>Maust</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Blow</surname><given-names>FC</given-names></string-name>. <article-title>Benzodiazepine use and misuse among adults in the United States</article-title>. <source>Psychiatr Serv</source><year>2019</year>; <volume>70</volume>(<issue>2</issue>): <fpage>97</fpage>&#8211;<lpage>106</lpage>.<pub-id pub-id-type="pmid">30554562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ps.201800321</pub-id><pub-id pub-id-type="pmcid">PMC6358464</pub-id></mixed-citation></ref><ref id="ref5"><label>5</label><mixed-citation publication-type="journal" id="cite5"><string-name name-style="western"><surname>Airagnes</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lemogne</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Renuy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Goldberg</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hoertel</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Roquelaure</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal><article-title>Prevalence of prescribed benzodiazepine long-term use in the French general population according to sociodemographic and clinical factors: findings from the CONSTANCES cohort</article-title>. <source>BMC Public Health</source><year>2019</year>; <volume>19</volume>(<issue>1</issue>): <fpage>566</fpage>&#8211;8.<pub-id pub-id-type="pmid">31088561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12889-019-6933-8</pub-id><pub-id pub-id-type="pmcid">PMC6518636</pub-id></mixed-citation></ref><ref id="ref6"><label>6</label><mixed-citation publication-type="journal" id="cite6"><string-name name-style="western"><surname>Votaw</surname><given-names>VR</given-names></string-name>, <string-name name-style="western"><surname>Geyer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rieselbach</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>McHugh</surname><given-names>RK</given-names></string-name>. <article-title>The epidemiology of benzodiazepine misuse: a systematic review</article-title>. <source>Drug Alcohol Depend</source><year>2019</year>; <volume>200</volume>: <fpage>95</fpage>&#8211;<lpage>114</lpage>.<pub-id pub-id-type="pmid">31121495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2019.02.033</pub-id><pub-id pub-id-type="pmcid">PMC6639084</pub-id></mixed-citation></ref><ref id="ref7"><label>7</label><mixed-citation publication-type="journal" id="cite7"><string-name name-style="western"><surname>Alessi-Severini</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bolton</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Enns</surname><given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Dahl</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Chateau</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>DM</given-names></string-name>, <etal>et al.</etal><article-title>Sustained use of benzodiazepines and escalation to high doses in a Canadian population</article-title>. <source>Psychiatr Serv</source><year>2016</year>; <volume>67</volume>(<issue>9</issue>): <fpage>1012</fpage>&#8211;8.<pub-id pub-id-type="pmid">27133727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ps.201500380</pub-id></mixed-citation></ref><ref id="ref8"><label>8</label><mixed-citation publication-type="journal" id="cite8"><string-name name-style="western"><surname>Offidani</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Guidi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tomba</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Fava</surname><given-names>GA</given-names></string-name>. <article-title>Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis</article-title>. <source>Psychother Psychosom</source><year>2013</year>; <volume>82</volume>(<issue>6</issue>): <fpage>355</fpage>&#8211;62.<pub-id pub-id-type="pmid">24061211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000353198</pub-id></mixed-citation></ref><ref id="ref9"><label>9</label><mixed-citation publication-type="journal" id="cite9"><string-name name-style="western"><surname>Maric</surname><given-names>NP</given-names></string-name>, <string-name name-style="western"><surname>Latas</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Andric Petrovic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Soldatovic</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Arsova</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Crnkovic</surname><given-names>D</given-names></string-name>, <etal>et al.</etal><article-title>Prescribing practices in Southeastern Europe &#8211; focus on benzodiazepine prescription at discharge from nine university psychiatric hospitals</article-title>. <source>Psychiatry Res</source><year>2017</year>; <volume>258</volume>: <fpage>59</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">28988045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psychres.2017.09.059</pub-id></mixed-citation></ref><ref id="ref10"><label>10</label><mixed-citation publication-type="journal" id="cite10"><string-name name-style="western"><surname>Takano</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ono</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yamana</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Matsui</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Matsumoto</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yasunaga</surname><given-names>H</given-names></string-name>, <etal>et al.</etal><article-title>Factors associated with long-term prescription of benzodiazepine: a retrospective cohort study using a health insurance database in Japan</article-title>. <source>BMJ Open</source><year>2019</year>; <volume>9</volume>(<issue>7</issue>): <fpage>e029641</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2019-029641</pub-id><pub-id pub-id-type="pmcid">PMC6661576</pub-id><pub-id pub-id-type="pmid">31350250</pub-id></mixed-citation></ref><ref id="ref11"><label>11</label><mixed-citation publication-type="journal" id="cite11"><string-name name-style="western"><surname>McGee</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Proctor</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Hart</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Burman</surname><given-names>M</given-names></string-name>. <article-title>Reconsidering benzodiazepines and Z-drug prescriptions: responsible prescribing and deprescribing</article-title>. <source>J Nurse Pract</source><year>2021</year>; <volume>17</volume>(<issue>1</issue>): <fpage>76</fpage>&#8211;<lpage>83</lpage>.</mixed-citation></ref><ref id="ref12"><label>12</label><mixed-citation publication-type="journal" id="cite12"><string-name name-style="western"><surname>Cloos</surname><given-names>J-M</given-names></string-name>, <string-name name-style="western"><surname>Lim Cow</surname><given-names>CYS</given-names></string-name>, <string-name name-style="western"><surname>Bocquet</surname><given-names>V</given-names></string-name>. <article-title>Benzodiazepine high-doses: the need for an accurate definition</article-title>. <source>Int J Methods Psychiatr Res</source><year>2021</year>; <volume>30</volume>(<issue>4</issue>): <fpage>e1888</fpage>.<pub-id pub-id-type="pmid">34331787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mpr.1888</pub-id><pub-id pub-id-type="pmcid">PMC8633930</pub-id></mixed-citation></ref><ref id="ref13"><label>13</label><mixed-citation publication-type="journal" id="cite13"><string-name name-style="western"><surname>Fride Tvete</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Bjorner</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Skomedal</surname><given-names>T</given-names></string-name>. <article-title>Risk factors for excessive benzodiazepine use in a working age population: a nationwide 5-year survey in Norway</article-title>. <source>Scand J Prim Health Care</source><year>2015</year>; <volume>33</volume>(<issue>4</issue>): <fpage>252</fpage>&#8211;9.<pub-id pub-id-type="pmid">26683285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/02813432.2015.1117282</pub-id><pub-id pub-id-type="pmcid">PMC4750734</pub-id></mixed-citation></ref><ref id="ref14"><label>14</label><mixed-citation publication-type="journal" id="cite14"><string-name name-style="western"><surname>Schepis</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Teter</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Simoni-Wastila</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>McCabe</surname><given-names>SE</given-names></string-name>. <article-title>Prescription tranquilizer/sedative misuse prevalence and correlates across age cohorts in the US</article-title>. <source>Addict Behav</source><year>2018</year>; <volume>87</volume>: <fpage>24</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">29940388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addbeh.2018.06.013</pub-id><pub-id pub-id-type="pmcid">PMC6527336</pub-id></mixed-citation></ref><ref id="ref15"><label>15</label><mixed-citation publication-type="journal" id="cite15"><string-name name-style="western"><surname>Cheng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Siddiqui</surname><given-names>TG</given-names></string-name>, <string-name name-style="western"><surname>Gossop</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kristoffersen</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Lundqvist</surname><given-names>C</given-names></string-name>. <article-title>Sociodemographic, clinical and pharmacological profiles of medication misuse and dependence in hospitalised older patients in Norway: a prospective cross-sectional study</article-title>. <source>BMJ Open</source><year>2019</year>; <volume>9</volume>(<issue>9</issue>): <fpage>e031483</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2019-031483</pub-id><pub-id pub-id-type="pmcid">PMC6731874</pub-id><pub-id pub-id-type="pmid">31492795</pub-id></mixed-citation></ref><ref id="ref16"><label>16</label><mixed-citation publication-type="other" id="cite16"><collab>WHO Collaborating Centre for Drug Statistics (WHOCC)</collab>. <italic toggle="yes">Structure and Principles</italic>. Norwegian Institute of Public Health, <year>2022</year> (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.whocc.no/atc/structure_and_principles/">https://www.whocc.no/atc/structure_and_principles/</uri> [cited 28 Oct 2021]).</mixed-citation></ref><ref id="ref17"><label>17</label><mixed-citation publication-type="journal" id="cite17"><string-name name-style="western"><surname>Tanskanen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Taipale</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Koponen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tolppanen</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Hartikainen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ahonen</surname><given-names>R</given-names></string-name>, <etal>et al.</etal><article-title>From prescription drug purchases to drug use periods &#8211; a second generation method (PRE2DUP)</article-title>. <source>BMC Med Inform Decis Mak</source><year>2015</year>; <volume>15</volume>: <fpage>21-z</fpage>.<pub-id pub-id-type="pmid">25890003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12911-015-0140-z</pub-id><pub-id pub-id-type="pmcid">PMC4382934</pub-id></mixed-citation></ref><ref id="ref18"><label>18</label><mixed-citation publication-type="other" id="cite18"><collab>World Health Organization (WHO)</collab>. <italic toggle="yes">Defined Daily Dose (DDD)</italic>. WHO, n.d. (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/tools/atc-ddd-toolkit/about-ddd">https://www.who.int/tools/atc-ddd-toolkit/about-ddd</uri> [cited 30 Aug 2021]).</mixed-citation></ref><ref id="ref19"><label>19</label><mixed-citation publication-type="journal" id="cite19"><string-name name-style="western"><surname>Zandstra</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Furer</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>van de Lisdonk</surname><given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>van't Hof</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bor</surname><given-names>JHJ</given-names></string-name>, <string-name name-style="western"><surname>van Weel</surname><given-names>C</given-names></string-name>, <etal>et al.</etal><article-title>Different study criteria affect the prevalence of benzodiazepine use</article-title>. <source>Soc Psychiatry Psychiatr Epidemiol</source><year>2014</year>; <volume>37</volume>(<issue>3</issue>): <fpage>139</fpage>&#8211;44.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s001270200006</pub-id><pub-id pub-id-type="pmid">11990011</pub-id></mixed-citation></ref><ref id="ref20"><label>20</label><mixed-citation publication-type="journal" id="cite20"><string-name name-style="western"><surname>Ashton</surname><given-names>H</given-names></string-name>. <article-title>The treatment of benzodiazepine dependence</article-title>. <source>Addiction</source><year>1994</year>; <volume>89</volume>(<issue>11</issue>): <fpage>1535</fpage>&#8211;41.<pub-id pub-id-type="pmid">7841868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1360-0443.1994.tb03755.x</pub-id></mixed-citation></ref><ref id="ref21"><label>21</label><mixed-citation publication-type="other" id="cite21"><collab>Statistics Finland</collab>. <italic toggle="yes">Classification of Occupations</italic>. Statistics Finland, <year>2010</year> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://stat.fi/en/luokitukset/ammatti/ammatti_1_20100101/?code=4&amp;name=Clericalsupportworkers" ext-link-type="uri">https://stat.fi/en/luokitukset/ammatti/ammatti_1_20100101/?code=4&amp;name=Clerical support workers</ext-link> [cited <date-in-citation content-type="access-date">31 Aug 2021</date-in-citation>]).</mixed-citation></ref><ref id="ref22"><label>22</label><mixed-citation publication-type="journal" id="cite22"><string-name name-style="western"><surname>Blanco</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Compton</surname><given-names>WM</given-names></string-name>. <article-title>Prevalence and correlates of benzodiazepine use, misuse, and use disorders among adults in the United States</article-title>. <source>J Clin Psychiatry</source><year>2018</year>; <volume>79</volume>(<issue>6</issue>): <fpage>18m12174</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4088/JCP.18m12174</pub-id><pub-id pub-id-type="pmcid">PMC10309967</pub-id><pub-id pub-id-type="pmid">30403446</pub-id></mixed-citation></ref><ref id="ref23"><label>23</label><mixed-citation publication-type="journal" id="cite23"><string-name name-style="western"><surname>Sidorchuk</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Isomura</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Molero</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hellner</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lichtenstein</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>Z</given-names></string-name>, <etal>et al.</etal><article-title>Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: a total population register-linkage study</article-title>. <source>PLoS Med</source><year>2018</year>; <volume>15</volume>(<issue>8</issue>): <fpage>e1002635</fpage>.<pub-id pub-id-type="pmid">30086134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1002635</pub-id><pub-id pub-id-type="pmcid">PMC6080748</pub-id></mixed-citation></ref><ref id="ref24"><label>24</label><mixed-citation publication-type="journal" id="cite24"><string-name name-style="western"><surname>Panes</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Verdoux</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Fourrier-R&#233;glat</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Berda&#239;</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pariente</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tournier</surname><given-names>M</given-names></string-name>. <article-title>Use of benzodiazepines non-compliant with guidelines in patients with psychiatric and non-psychiatric chronic disorders</article-title>. <source>Gen Hosp Psychiatry</source><year>2020</year>; <volume>65</volume>: <fpage>21</fpage>&#8211;7.<pub-id pub-id-type="pmid">32408031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.genhosppsych.2020.03.006</pub-id></mixed-citation></ref><ref id="ref25"><label>25</label><mixed-citation publication-type="journal" id="cite25"><string-name name-style="western"><surname>Ogawa</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Takeshima</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hayasaka</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tajika</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Watanabe</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Streiner</surname><given-names>D</given-names></string-name>, <etal>et al.</etal><article-title>Antidepressants plus benzodiazepines for adults with major depression</article-title>. <source>Cochrane Database Syst Rev</source><year>2019</year>; <volume>2019</volume>(<issue>6</issue>): <fpage>CD001026</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD001026.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6546439</pub-id><pub-id pub-id-type="pmid">31158298</pub-id></mixed-citation></ref><ref id="ref26"><label>26</label><mixed-citation publication-type="journal" id="cite26"><string-name name-style="western"><surname>Tor</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Ng</surname><given-names>TP</given-names></string-name>, <string-name name-style="western"><surname>Yong</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Sim</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>YT</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>CY</given-names></string-name>, <etal>et al.</etal><article-title>Adjunctive benzodiazepine treatment of hospitalized schizophrenia patients in Asia from 2001 to 2008</article-title>. <source>Int J Neuropsychopharmacol</source><year>2011</year>; <volume>14</volume>(<issue>6</issue>): <fpage>735</fpage>&#8211;45.<pub-id pub-id-type="pmid">21294941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S146114571000163X</pub-id></mixed-citation></ref><ref id="ref27"><label>27</label><mixed-citation publication-type="journal" id="cite27"><string-name name-style="western"><surname>Zhong</surname><given-names>XM</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Ungvari</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Ng</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Chiu</surname><given-names>HFK</given-names></string-name>, <etal>et al.</etal><article-title>Concurrent benzodiazepine use in older adults treated with antidepressants in Asia</article-title>. <source>Int psychogeriatrics</source><year>2019</year>; <volume>31</volume>(<issue>5</issue>): <fpage>685</fpage>&#8211;91.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610217002563</pub-id><pub-id pub-id-type="pmid">29212560</pub-id></mixed-citation></ref><ref id="ref28"><label>28</label><mixed-citation publication-type="journal" id="cite28"><string-name name-style="western"><surname>Chen</surname><given-names>YT</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>YM</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>BH</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>TY</given-names></string-name>, <etal>et al.</etal><article-title>Perceptions, clinical characteristics, and other factors associated with prolonged and high daily dose of benzodiazepine use among patients with anxiety or depressive disorders</article-title>. <source>J Affect Disord</source><year>2020</year>; <volume>271</volume>: <fpage>215</fpage>&#8211;23.<pub-id pub-id-type="pmid">32479319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2020.03.077</pub-id></mixed-citation></ref><ref id="ref29"><label>29</label><mixed-citation publication-type="journal" id="cite29"><string-name name-style="western"><surname>McHugh</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Peckham</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Bj&#246;rgvinsson</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Korte</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Beard</surname><given-names>C</given-names></string-name>. <article-title>Benzodiazepine misuse among adults receiving psychiatric treatment</article-title>. <source>J Psychiatr Res</source><year>2020</year>; <volume>128</volume>: <fpage>33</fpage>&#8211;7.<pub-id pub-id-type="pmid">32516628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpsychires.2020.05.020</pub-id><pub-id pub-id-type="pmcid">PMC7483788</pub-id></mixed-citation></ref><ref id="ref30"><label>30</label><mixed-citation publication-type="journal" id="cite30"><string-name name-style="western"><surname>Bushnell</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Rynn</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Crystal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gerhard</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Olfson</surname><given-names>M</given-names></string-name>. <article-title>Simultaneous benzodiazepine and SSRI initiation in young people with anxiety disorders</article-title>. <source>J Clin Psychiatry</source><year>2021</year>; <volume>82</volume>(<issue>6</issue>): <fpage>37519</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4088/JCP.20m13863</pub-id><pub-id pub-id-type="pmcid">PMC9382882</pub-id><pub-id pub-id-type="pmid">34670029</pub-id></mixed-citation></ref><ref id="ref31"><label>31</label><mixed-citation publication-type="other" id="cite31"><collab>National Institute for Health and Care Excellence (NICE)</collab>. <italic toggle="yes">Generalised Anxiety Disorder and Panic Disorder in Adults: Management. NICE Clinical Guidelines, No. 113</italic>. Nice, <year>2019</year> (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK552847/">https://www.ncbi.nlm.nih.gov/books/NBK552847/</uri> [cited 14 Dec 2022]).<pub-id pub-id-type="pmid">31961629</pub-id></mixed-citation></ref><ref id="ref32"><label>32</label><mixed-citation publication-type="journal" id="cite32"><string-name name-style="western"><surname>Agarwal</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Landon</surname><given-names>BE</given-names></string-name>. <article-title>Patterns in outpatient benzodiazepine prescribing in the United States</article-title>. <source>JAMA Netw Open</source><year>2019</year>; <volume>2</volume>(<issue>1</issue>): <fpage>e187399</fpage>.<pub-id pub-id-type="pmid">30681713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2018.7399</pub-id><pub-id pub-id-type="pmcid">PMC6484578</pub-id></mixed-citation></ref><ref id="ref33"><label>33</label><mixed-citation publication-type="journal" id="cite33"><string-name name-style="western"><surname>Zaami</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Graziano</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tittarelli</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Beck</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Marinelli</surname><given-names>E</given-names></string-name>. <article-title>BDZs, designer BDZs, and Z-drugs: pharmacology and misuse insights</article-title>. <source>Curr Pharm Des</source><year>2021</year>; <volume>28</volume>(<issue>15</issue>): <fpage>1221</fpage>&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1381612827666210917145636</pub-id><pub-id pub-id-type="pmid">34533440</pub-id></mixed-citation></ref><ref id="ref34"><label>34</label><mixed-citation publication-type="journal" id="cite34"><string-name name-style="western"><surname>Chouinard</surname><given-names>G</given-names></string-name>. <article-title>Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound</article-title>. <source>J Clin Psychiatry</source><year>2004</year>; <volume>65</volume>(<issue>Suppl 5</issue>): <fpage>7</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">15078112</pub-id></mixed-citation></ref><ref id="ref35"><label>35</label><mixed-citation publication-type="journal" id="cite35"><string-name name-style="western"><surname>Frauger</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Pauly</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Pradel</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Rouby</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Arditti</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Thirion</surname><given-names>X</given-names></string-name>, <etal>et al.</etal><article-title>Evidence of clonazepam abuse liability: results of the tools developed by the French centers for evaluation and information on pharmacodependence (CEIP) network</article-title>. <source>Fundam Clin Pharmacol</source><year>2011</year>; <volume>25</volume>(<issue>5</issue>): <fpage>633</fpage>&#8211;41.<pub-id pub-id-type="pmid">21077937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1472-8206.2010.00882.x</pub-id></mixed-citation></ref><ref id="ref36"><label>36</label><mixed-citation publication-type="journal" id="cite36"><string-name name-style="western"><surname>Dokkedal-Silva</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Berro</surname><given-names>LF</given-names></string-name>, <string-name name-style="western"><surname>Galdur&#243;z</surname><given-names>JCF</given-names></string-name>, <string-name name-style="western"><surname>Tufik</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Andersen</surname><given-names>ML</given-names></string-name>. <article-title>Clonazepam: indications, side effects, and potential for nonmedical use</article-title>. <source>Harv Rev Psychiatry</source><year>2019</year>; <volume>27</volume>(<issue>5</issue>): <fpage>279</fpage>&#8211;89.<pub-id pub-id-type="pmid">31385811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/HRP.0000000000000227</pub-id></mixed-citation></ref><ref id="ref37"><label>37</label><mixed-citation publication-type="journal" id="cite37"><string-name name-style="western"><surname>McCabe</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Veliz</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Boyd</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Schulenberg</surname><given-names>JE</given-names></string-name>. <article-title>Medical and nonmedical use of prescription sedatives and anxiolytics: adolescents&#8217; use and substance use disorder symptoms in adulthood</article-title>. <source>Addict Behav</source><year>2017</year>; <volume>65</volume>: <fpage>296</fpage>&#8211;<lpage>301</lpage>.<pub-id pub-id-type="pmid">27569697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addbeh.2016.08.021</pub-id><pub-id pub-id-type="pmcid">PMC5462596</pub-id></mixed-citation></ref><ref id="ref38"><label>38</label><mixed-citation publication-type="journal" id="cite38"><string-name name-style="western"><surname>Hulme</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bright</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Nielsen</surname><given-names>S</given-names></string-name>. <article-title>The source and diversion of pharmaceutical drugs for non-medical use: a systematic review and meta-analysis</article-title>. <source>Drug Alcohol Depend</source><year>2018</year>; <volume>186</volume>: <fpage>242</fpage>&#8211;56.<pub-id pub-id-type="pmid">29626777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2018.02.010</pub-id></mixed-citation></ref><ref id="ref39"><label>39</label><mixed-citation publication-type="journal" id="cite39"><string-name name-style="western"><surname>Haukka</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Suvisaari</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tuulio-Henriksson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>L&#246;nnqvist</surname><given-names>J</given-names></string-name>. <article-title>High concordance between self-reported medication and official prescription database information</article-title>. <source>Eur J Clin Pharmacol</source><year>2007</year>; <volume>63</volume>(<issue>11</issue>): <fpage>1069</fpage>&#8211;74.<pub-id pub-id-type="pmid">17712552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-007-0349-6</pub-id></mixed-citation></ref><ref id="ref40"><label>40</label><mixed-citation publication-type="journal" id="cite40"><string-name name-style="western"><surname>Votaw</surname><given-names>VR</given-names></string-name>, <string-name name-style="western"><surname>McHugh</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Vowles</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Witkiewitz</surname><given-names>K</given-names></string-name>. <article-title>Patterns of polysubstance use among adults with tranquilizer misuse</article-title>. <source>Subst Use Misuse</source><year>2020</year>; <volume>55</volume>(<issue>6</issue>): <fpage>861</fpage>&#8211;70.<pub-id pub-id-type="pmid">31900021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10826084.2019.1708118</pub-id><pub-id pub-id-type="pmcid">PMC7166167</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>